Advances in biotechnology, a greater understanding of the immunopathogenesis of rheumatoid arthritis (RA) and a desire for more effective therapeutics have led to the development of a class of ...

Biologic vs conventional DMARDs may offer cardioprotective benefits among patients with PsA, though an increased risk for infection requires vigilance.

Please provide your email address to receive an email when new articles are posted on . EULAR recommendations on pharmacological PsA management cover all available drugs in a “practical and ...

SaveHealth reports on psoriatic arthritis medications, detailing options like DMARDs, biologics, and NSAIDs, including their ...

Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the ...

In recent years, the treatment of rheumatic inflammatory diseases has been revolutionized. With the advent of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), minimal ...

Rheumatoid arthritis (RA) disease activity and inflammatory markers are associated with major adverse cardiovascular events (MACEs) in biologic disease-modifying antirheumatic drug (bDMARD) nonusers ...

Biologic agents have been used to treat rheumatoid arthritis (RA) for more than a decade. Their use has dramatically expanded the therapeutic options, leading to unprecedented clinical, structural and ...

The US Food and Drug Administration (FDA) has approved more than 23,000 prescription drugs, with many more in development. Increasingly, therapeutic manufacturers are discovering that the key to ...

Although methotrexate was linked with a higher risk of anemia, it carried risks of kidney and other serious infections similar to those of biologics. The use of methotrexate (MTX) for routine care in ...